What's the Outlook for Illumina?

·3 min read

Genomic sequencing leader Illumina (NASDAQ: ILMN) recently provided guidance for 2022 and revealed some of its plans for the year. In this Motley Fool Live video, recorded on Jan. 12, Fool contributors Keith Speights and Brian Orelli discuss the outlook for Illumina going forward. Keith Speights: Hey, there's a company that you and I haven't talked about very much, at least, I'm going to say at least over the last seven or eight months and maybe longer than that.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting